Polyendocrine-metabolic ovarian syndrome (PMOS) is an endocrine-metabolic disorder affecting 8–13% of women of reproductive age. Key factors involved in the pathophysiology of this syndrome include hyperandrogenism, insulin resistance, ovarian dysfunction, and oxidative stress. In recent years, research has focused particularly on the role of mitochondrial dysfunction and oxidative stress in the syndrome's pathophysiology. Preclinical and clinical studies have linked these processes to increased production of reactive oxygen species, reduced antioxidant defenses, impaired insulin sensitivity, altered energy metabolism, and mitochondrial DNA alterations, including copy number variations and mutations. At the oocyte level, impaired oocyte maturation, compromised follicular development, and reduced embryo quality have been observed. These alterations can contribute to anovulation and infertility, which are characteristic manifestations of PMOS. Certain phytocompounds, including resveratrol, astaxanthin, and curcumin, have shown promising effects in modulating mitochondrial dysfunction and oxidative stress. Evidence also suggests that these three compounds may impact oocyte quality. Resveratrol has been associated with significant improvements in specific markers of mitochondrial biogenesis, as well as increased rates of oocyte maturation and a higher percentage of high-quality embryos. Astaxanthin has shown beneficial effects on certain biomarkers related to mitochondrial function and an increase in the oocyte maturation rate, although the observed effects were not consistent across all parameters considered. Favorable results regarding the modulation of oxidative stress also emerged for curcumin, although clinical evidence in women with PMOS remains limited. Overall, the analyzed results suggest that these three phytocompounds are of potential interest for modulating the mitochondrial dysfunction and oxidative stress associated with PMOS; however, further studies are needed to define their role and clinical relevance.
La sindrome ovarica poliendocrino-metabolica (PMOS) è un disturbo endocrino-metabolico che colpisce l’8-13% delle donne in età riproduttiva. Tra i principali fattori coinvolti nella fisiopatologia di questa sindrome vi sono l’iperandrogenismo, l’insulino-resistenza, la disfunzione ovarica e lo stress ossidativo. Negli ultimi anni, la ricerca ha posto particolare attenzione al ruolo della disfunzione mitocondriale e dello stress ossidativo nella fisiopatologia della sindrome. Studi preclinici e clinici hanno correlato questi processi ad un aumento della produzione di specie reattive dell’ossigeno, alla riduzione delle difese antiossidanti, alla compromissione della sensibilità insulinica, all’alterazione del metabolismo energetico e ad alterazioni del DNA mitocondriale, comprese variazioni del numero di copie e mutazioni. A livello ovocitario è stata evidenziata un’alterata maturazione degli ovociti, un compromesso sviluppo follicolare e una ridotta qualità embrionale. Queste alterazioni possono contribuire all’anovulazione e all’infertilità, manifestazioni caratteristiche della PMOS. Alcuni fitocomposti, tra cui il resveratrolo, l’astaxantina e la curcumina, hanno mostrato effetti di interesse nella modulazione della disfunzione mitocondriale e dello stress ossidativo. Per i tre composti sono emerse anche evidenze di potenziali effetti sulla qualità ovocitaria. Il resveratrolo è stato associato ad un miglioramento significativo di alcuni marker della biogenesi mitocondriale, oltre che ad un aumento del tasso di maturazione ovocitaria e della percentuale di embrioni di qualità. L’astaxantina ha evidenziato effetti favorevoli su alcuni biomarcatori correlati alla funzione mitocondriale e un aumento del tasso di maturazione ovocitaria, sebbene gli effetti osservati non siano risultati uniformi per tutti i parametri considerati. Anche per la curcumina sono emersi risultati favorevoli sulla modulazione dello stress ossidativo, sebbene le evidenze cliniche nelle donne affette da PMOS risultino ancora limitate. Complessivamente, i risultati analizzati suggeriscono un potenziale interesse dei tre fitocomposti nella modulazione della disfunzione mitocondriale e dello stress ossidativo associati alla PMOS; tuttavia, sono necessari ulteriori studi per definirne il ruolo e la rilevanza clinica.
Disfunzione mitocondriale e stress ossidativo nella sindrome ovarica poliendocrino-metabolica: impatto sulla qualità ovocitaria e potenziale ruolo dei fitocomposti bioattivi
LUNARDON, CHIARA
2025/2026
Abstract
Polyendocrine-metabolic ovarian syndrome (PMOS) is an endocrine-metabolic disorder affecting 8–13% of women of reproductive age. Key factors involved in the pathophysiology of this syndrome include hyperandrogenism, insulin resistance, ovarian dysfunction, and oxidative stress. In recent years, research has focused particularly on the role of mitochondrial dysfunction and oxidative stress in the syndrome's pathophysiology. Preclinical and clinical studies have linked these processes to increased production of reactive oxygen species, reduced antioxidant defenses, impaired insulin sensitivity, altered energy metabolism, and mitochondrial DNA alterations, including copy number variations and mutations. At the oocyte level, impaired oocyte maturation, compromised follicular development, and reduced embryo quality have been observed. These alterations can contribute to anovulation and infertility, which are characteristic manifestations of PMOS. Certain phytocompounds, including resveratrol, astaxanthin, and curcumin, have shown promising effects in modulating mitochondrial dysfunction and oxidative stress. Evidence also suggests that these three compounds may impact oocyte quality. Resveratrol has been associated with significant improvements in specific markers of mitochondrial biogenesis, as well as increased rates of oocyte maturation and a higher percentage of high-quality embryos. Astaxanthin has shown beneficial effects on certain biomarkers related to mitochondrial function and an increase in the oocyte maturation rate, although the observed effects were not consistent across all parameters considered. Favorable results regarding the modulation of oxidative stress also emerged for curcumin, although clinical evidence in women with PMOS remains limited. Overall, the analyzed results suggest that these three phytocompounds are of potential interest for modulating the mitochondrial dysfunction and oxidative stress associated with PMOS; however, further studies are needed to define their role and clinical relevance.| File | Dimensione | Formato | |
|---|---|---|---|
|
Lunardon_Chiara.pdf
accesso aperto
Dimensione
1.21 MB
Formato
Adobe PDF
|
1.21 MB | Adobe PDF | Visualizza/Apri |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/117743